{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:19:25Z","timestamp":1788542365073,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>To explore the independent influencing factors of PCa bone metastasis and evaluate the role of prostate imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      The clinic data such as age, prostate volume,\n                      <jats:italic toggle=\"yes\">tPSA<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">fPSA<\/jats:italic>\n                      . Univariate and multivariate analyses were performed to investigate the independent influencing point of the risk factors. Nomogram and ROC curve were generated to establish the prediction model. The calibration curve, leave-one-out cross validation and independent external validation were performed to evaluate the prediction model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      This study enrolled 325 newly diagnosed PCa patients at two hospitals. Univariate and multivariate analyses showed only\n                      <jats:italic toggle=\"yes\">tPSA<\/jats:italic>\n                      , cTx, ALP, and PI-RADS v2 score were the independent influencing factors of PCa bone metastasis. The cut-off points of PI-RADS v2 score to distinguish bone metastasis was 5. The nomogram was established with a sensitivity of 81.3% and a specificity of 74.5% to predict the probability of PCa bone metastasis. The calibration curve and ROC curve displayed a good value of the prediction model. Leave-one-outcross validation showed the prediction model could classify 79.8% cases accurately. External data validation displayed sensitivity of 78.4% and a specificity of 79.1%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>PI-RADS v2 score could predict PCa bone metastasis, the prediction model may help discovered PCa bone metastasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijc.ijc_1015_22","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:00:30Z","timestamp":1781071230000},"page":"82-89","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["PI-RADS v2 score may be as a predictor of bone metastasis in prostate cancer"],"prefix":"10.4103","volume":"63","author":[{"given":"Ting","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng H.","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"R1-20260904","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260904","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"R3-20260904","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000368912","article-title":"Is it safe to omit baseline bone scan for newly diagnosed prostate cancer patients?","volume":"94","author":"Wang","year":"2015","journal-title":"Urol Int"},{"key":"R4-20260904","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.eururo.2006.07.012","article-title":"Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial","volume":"51","author":"Aus","year":"2007","journal-title":"Eur Urol"},{"key":"R5-20260904","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","article-title":"Skeletal related events, bone metastasis and survival of prostate cancer: A population based cohort study in Denmark (1999 to 2007)","volume":"184","author":"N\u00f8rgaard","year":"2010","journal-title":"J Urol"},{"key":"R6-20260904","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/aja.2013.111","article-title":"Clinical features and treatment strategies for older prostate cancer patients with bone metastasis","volume":"15","author":"Yang","year":"2013","journal-title":"Asian J Androl"},{"key":"R7-20260904","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"R8-20260904","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.eururo.2009.12.023","article-title":"When to perform bone scan in patients with newly diagnosed prostate cancer: External validation of the currently available guidelines and proposal of a novel risk stratification tool","volume":"57","author":"Briganti","year":"2010","journal-title":"Eur Urol"},{"key":"R9-20260904","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.urolonc.2009.05.007","article-title":"Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: Feasibility in Asian population","volume":"29","author":"Lai","year":"2011","journal-title":"Urol Oncol"},{"key":"R10-20260904","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00345-011-0728-6","article-title":"Is it suitable to eliminate bone scan for prostate cancer patients with PSA<\/=20 ng\/mL?","volume":"30","author":"Lee","year":"2012","journal-title":"World J Urol"},{"key":"R11-20260904","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/jjco\/hyr118","article-title":"Bone scan can be spared in asymptomatic prostate cancer patients with PSA of <=20 ng\/ml and Gleason score of <=6 at the initial stage of diagnosis","volume":"41","author":"Tanaka","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"R12-20260904","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12894-017-0229-z","article-title":"When to perform bone scintigraphy in patients with newly diagnosed prostate cancer?a retrospective study","volume":"17","author":"Lin","year":"2017","journal-title":"BMC Urol"},{"key":"R13-20260904","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.12659\/MSM.900977","article-title":"Associations of prostate-specific antigen, prostate carcinoma tissue Gleason score, and androgen receptor expression with bone metastasis in patients with prostate carcinoma","volume":"23","author":"Chen","year":"2017","journal-title":"Med Sci Monit"},{"key":"R14-20260904","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS prostate imaging - reporting and data system:2015, Version 2","volume":"69","author":"Weinreb","year":"2016","journal-title":"Eur Urol"},{"key":"R15-20260904","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1148\/radiol.16151133","article-title":"Prostate cancer: PI-RADS version 2 Helps preoperatively predict clinically significant cancers","volume":"280","author":"Park","year":"2016","journal-title":"Radiology"},{"key":"R16-20260904","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.juro.2017.03.131","article-title":"Prospective evaluation of PI-RADSTM version 2 using the International Society of Urological Pathology Prostate Cancer Grade Group System","volume":"198","author":"Mehralivand","year":"2017","journal-title":"J Urol"},{"key":"R17-20260904","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.2214\/AJR.16.16981","article-title":"PI-RADS Version 2: Detection of Clinically Significant Cancer in Patients with Biopsy Gleason Score 6 Prostate Cancer","volume":"209","author":"Seo","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"R18-20260904","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.7150\/ijms.45730","article-title":"The prediction value of PI-RADS v2 score in high-grade prostate cancer: A multicenter retrospective study","volume":"17","author":"Chen","year":"2020","journal-title":"Int J Med Sci"},{"key":"R19-20260904","doi-asserted-by":"crossref","first-page":"208","DOI":"10.7150\/ijbs.27537","article-title":"Establishing a prediction model for prostate cancer bone metastasis","volume":"15","author":"Chen","year":"2019","journal-title":"Int J Biol Sci"},{"key":"R21-20260904","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","article-title":"The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma","volume":"29","author":"Epstein","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R22-20260904","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","article-title":"Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Parker","year":"2015","journal-title":"Ann Oncol"},{"key":"R23-20260904","doi-asserted-by":"crossref","first-page":"584","DOI":"10.21037\/tau-20-989","article-title":"Predictive model containing PI-RADS v2 score for postoperative seminal vesicle invasion among prostate cancer patients","volume":"10","author":"Wang","year":"2021","journal-title":"Transl Androl Urol"},{"key":"R24-20260904","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.21037\/tau-21-49","article-title":"A nomogram based on PI-RADS v2.1 and clinical indicators for predicting clinically significant prostate cancer in the transition zone","volume":"10","author":"Wei","year":"2021","journal-title":"Transl Androl Urol"},{"key":"R25-20260904","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.crad.2016.12.005","article-title":"Developing a new PI-RADS v2-based nomogram for forecasting high-grade prostate cancer","volume":"72","author":"Niu","year":"2017","journal-title":"Clin Radiol"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.ijc_1015_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:02:42Z","timestamp":1788541362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.ijc_1015_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_1015_22","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2022-09-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}